MNLO Research and Charts

MNLO - Menlo Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2020-11-04 (Delayed quote data 2025-06-26)

Last 1.62	Change ⇑ +0.25 (+18.25%)	Volume 4,977,458
	Open 1.39	High 1.75	Low 1.36

8EMA (Daily) 1.17	40EMA (Daily) 1.17	50EMA (Daily) 1.24	STO (Daily) 57.845	MACD Hist (Daily) 0.170
8EMA (Weekly) 1.219	40EMA (Weekly) 1.87	50EMA (Weekly) 1.97	STO (Weekly) 15.570	MACD Hist (Weekly) -0.003


Company Profile
Menlo Therapeutics Inc is a US-based late-stage biopharmaceutical company which focuses on the development and commercialization of Serlopitant for the treatment of pruritus associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The pipeline product of the company includes Prurigo Nodularis, Prurigo Dermatitis, Psoriasis and Refractory Chronic Cough.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.